Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.67 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11136814 | 0.85 | AURKA (0.58) | AURKAAURKBCAMK2DNPC1RAB9A | |
| SCHEMBL21725113 | 0.83 | AURKA (0.49) | AURKAAURKBCAMK2D | |
| SCHEMBL21724333 | 0.83 | MAPK8 (0.64) | AURKAAURKBGSK3BIKBKB | |
| SCHEMBL1023029 | 0.82 | NPC1 (0.71) | AURKAAURKBCAMK2DNPC1RAB9A | |
| SCHEMBL17512579 | 0.81 | AURKA (0.72) | AURKAAURKBCAMK2DNPC1RAB9A | |
| SCHEMBL4569980 | 0.81 | RHOA (0.72) | AURKAAURKBCAMK2DNPC1RAB9A | |
| SCHEMBL3645658 | 0.80 | GSK3B (0.61) | AURKAAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4872174 | 0.80 | HCAR3 (0.63) | AURKAAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29874885 | 0.80 | NPC1 (0.69) | AURKAAURKBCAMK2DNPC1RAB9A | |
| SCHEMBL13502763 | 0.80 | AURKA (0.75) | AURKAAURKBCAMK2DNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| CN-101223130-A | Glutamate aggrecanase inhibitors | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | AURKA 1290/4885AURKB 1058/4885CAMK2D 365/4885 |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | AURKA 496/4885AURKB 667/4885CAMK2D 4340/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | AURKA 1290/4885AURKB 1058/4885CAMK2D 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.